STOCK TITAN
  1. Home
  2. Sec-filings
  3. NEO
  4. [8-K] NeoGenomics, Inc. Reports Material Event

Healthcare Diagnostics Leader NeoGenomics Strengthens Board with Key Appointment

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

NeoGenomics has announced a significant board expansion and appointment in a Form 8-K filing. The company's Board of Directors has increased its size from nine to ten members with the appointment of Marjorie C. Green as a new director, effective June 19, 2025.

Key details of the appointment include:

  • Ms. Green will serve until the 2026 annual meeting of stockholders or until resignation/removal
  • She will receive compensation aligned with the company's existing independent director compensation program as disclosed in the 2025 proxy statement
  • The appointment was publicly announced via press release on June 24, 2025

The filing, signed by EVP and General Counsel Alicia C. Olivo, includes standard regulatory disclosures and confirms that NeoGenomics is not classified as an emerging growth company. The company trades on the Nasdaq Stock Market under the symbol NEO.

Positive

  • Board expansion and appointment of Marjorie C. Green as new director, increasing board diversity and oversight capabilities

Negative

  • None.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Understanding 8-K Material Events →
0001077183FALSE00010771832025-06-192025-06-19

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549 
 
FORM 8-K  
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
June 19, 2025
 
NEOGENOMICS, INC.
(Exact name of registrant as specified in its charter) 
 
Nevada
001-35756
74-2897368
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)

 
9490 NeoGenomics Way,Fort Myers,Florida33912
(Address of principal executive offices)(Zip Code)
(239) 768-0600
(Registrant’s telephone number, including area code) 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:Trading Symbol(s):Name of each exchange on which registered:
Common Stock, par value $0.001 per shareNEOThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 


Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On June 19, 2025, the Board of Directors of NeoGenomics, Inc. (the "Company") increased the size of the Board of Directors (the "Board") from nine to ten members and appointed Marjorie C. Green as a director to fill the vacancy resulting from that increase.
Ms. Green will serve as a member of the Board until the 2026 annual meeting of stockholders of the Company or until her resignation or removal and otherwise until her successor is elected. Ms. Green will receive compensation for their service as independent directors consistent with the Company's director compensation program previously disclosed in the Company's definitive proxy statement for its 2025 annual meeting of stockholders.
Item 7.01Regulation FD Disclosure
On June 24, 2025, the Company issued a press release regarding the foregoing, which is attached to the Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.
This information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01Financial Statements and Exhibits.
(a)
Not applicable
(b)
Not applicable
(c)
Not applicable
(d)
Exhibits.
99.1
Press Release of NeoGenomics, Inc. dated June 24, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
NEOGENOMICS, INC.
Date:June 24, 2025
By:
/s/ Alicia C. Olivo
Alicia C. Olivo
EVP, General Counsel & Business Development
and Corporate Secretary



Source: View Original Filing on SEC EDGAR

FAQ

Who is the new board member appointed to NEO's Board of Directors in June 2025?

Marjorie C. Green was appointed as a new director to NeoGenomics' Board of Directors on June 19, 2025, increasing the board size from nine to ten members.

How long will Marjorie Green serve on NEO's Board of Directors?

Ms. Green will serve as a board member until the 2026 annual meeting of stockholders, or until her resignation or removal and otherwise until her successor is elected.

What compensation will NEO's new director Marjorie Green receive?

Ms. Green will receive compensation consistent with NeoGenomics' director compensation program for independent directors, as previously disclosed in the company's definitive proxy statement for its 2025 annual meeting of stockholders.

When did NEO announce the new board member appointment to the public?

NeoGenomics issued a press release regarding the board appointment on June 24, 2025, which was filed as Exhibit 99.1 to the 8-K.

What is the current size of NEO's Board of Directors after the new appointment?

Following the appointment of Marjorie C. Green, NeoGenomics' Board of Directors increased from nine to ten members.